Acorda therapeutics to provide update on clinical development
pipeline at upcoming r&d day
Ardsley, n.y.--(business wire)--acorda therapeutics, inc. (nasdaq:acor) will host a research and development (r&d) day for the investment community on tuesday, november 5, 2013 from 9:00 a.m. to 12:00 p.m. at alexandria center for life sciences in new york city (450 east 29th street at first avenue). members of acorda’s management team, including president and ceo ron cohen, m.d., chief scientific officer andrew blight, ph.d., chief medical officer enrique carrazana., m.d., and vp, research and development anthony caggiano, m.d., ph.d., will review acorda’s six clinical-stage programs. presentations will include development programs in post-stroke deficits, cluster seizures, heart failure, neuropathic pain, multiple sclerosis and spinal cord injury. independent experts in the fields of heart failure, epilepsy, post stroke deficits and remyelination will provide their perspectives on disease state and current standards of care in their respective therapeutic area. a live audio webcast of the presentation can be accessed under “investor events” in the investor section of the acorda website at www.acorda.com or available via the following link prior to the start of the event: http://www.media-server.com/m/p/ic98q9dq the webcast of the presentation and copies of the slideshow will be available after the event by accessing the investor section of www.acorda.com. about acorda therapeutics founded in 1995, acorda therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological conditions. acorda markets three fda-approved therapies including: ampyra® (dalfampridine) extended release tablets, 10 mg, a treatment to improve walking in patients with multiple sclerosis (ms); zanaflex capsules® (tizanidine hydrochloride) and zanaflex tablets, a short-acting drug for the management of spasticity; and qutenza® (capsaicin) 8% patch, for the management of neuropathic pain associated with postherpetic neuralgia. ampyra is marketed outside the united states as fampyra® (prolonged-release fampridine tablets) by biogen idec under a licensing agreement from acorda. acorda has one of the leading pipelines in the industry of novel neurological therapies. the company is currently developing six clinical-stage therapies and one preclinical stage therapy that address a range of disorders including post-stroke deficits, epilepsy, cerebral palsy, stroke, peripheral nerve damage, spinal cord injury, neuropathic pain, and heart failure. for more information, please visit the company’s website at: www.acorda.com. forward-looking statements this press release includes forward-looking statements within the meaning of the private securities litigation reform act of 1995. all statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. these statements are subject to risks and uncertainties that could cause actual results to differ materially, including our ability to successfully market and sell ampyra in the u.s.; third party payers (including governmental agencies) may not reimburse for the use of ampyra or our other products at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; the risk of unfavorable results from future studies of ampyra or from our other research and development programs, including diazepam nasal spray or any other acquired or in-licensed programs; we may not be able to complete development of, obtain regulatory approval for, or successfully market diazepam nasal spray or other products under development; the occurrence of adverse safety events with our products; delays in obtaining or failure to obtain regulatory approval of or to successfully market fampyra outside of the u.s. and our dependence on our collaboration partner biogen idec in connection therewith; competition, including the impact of generic competition on zanaflex capsules revenues; failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third party intellectual property licenses needed for the commercialization of our products; failure to comply with regulatory requirements could result in adverse action by regulatory agencies; and the ability to obtain additional financing to support our operations. these and other risks are described in greater detail in acorda therapeutics' filings with the securities & exchange commission. acorda may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. forward-looking statements made in this release are made only as of the date hereof, and acorda disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this release.
